Company news
Marvel Biosciences Corp (TSXV:MRVL) news
Marvel Biosciences Corp news releases on 6ix. Latest, Jan 8, 2024: Marvel Biosciences to Collaborate with Tau Expert Dr. Emmanuel Planel
Press releases — page 2
Marvel Biosciences to Collaborate with Tau Expert Dr. Emmanuel Planel
January 8, 2024
Marvel Biosciences Invited to Test MB-204 on Autism by French University
November 16, 2023
Marvel Announces Successful Completion of Toxicology Study in Preparation for Phase 1 Human Trials
August 22, 2023
Marvel Highlights Key Asset at the 2023 Alzheimer's Association International Conference
July 10, 2023
Marvel Successfully Completes the Dog and Rat GLP Toxicology Studies Required to Enter Human Trials
April 20, 2023
Marvel Commences Final Study Required Prior to Initiating Human Trials
March 21, 2023
Marvel Biosciences Initiates Four Week Rat GLP Toxicology Study
March 9, 2023
Marvel Biosciences Announces Closing of First Tranche of Debenture Offering
February 24, 2023
Marvel Biosciences Announces Proposed Debenture Offering
February 15, 2023
Marvel Biosciences Completes a Critical Manufacturing Milestone Required to Enter Phase 1 Human Trials Targeting Alzheimer's Disease and Depression
January 6, 2023
Marvel Biosciences Successfully Completes its Short Term Dose Ranging Study in Rats and Dogs for MB-204
January 3, 2023
Marvel Biosciences Announces Letter Agreement for Market Stabilization and Liquidity Services
December 23, 2022
Marvel Biosciences Announces Stock Option Grant
December 20, 2022
Marvel Biosciences Initiates Its Final FDA-Required Experiment Prior to Initiating Human Trials for Its Lead Drug Candidate MB-204
December 12, 2022
Marvel Biosciences Initiates the Next Milestone Study for its Lead Asset MB-204 Targeting Alzheimer's and Depression
December 7, 2022
Marvel Biosciences Announces Director Appointment and Resignation
November 24, 2022
Marvel Biosciences' Lead Drug Candidate MB-204 Demonstrates a 400% Increase in the Survival Rate of Animals Treated with a High Dose of the Cancer Treatment Cis-Platinum
November 22, 2022
Marvel Biosciences Lead Drug Candidate MB-204 Demonstrated Superior Anti-Anxiety Activity over FDA-Approved Istradefylline in Head-To-Head Pre-Clinical Studies
November 14, 2022
Marvel Biosciences' Lead Drug Candidate MB-204 Successfully Targets Brain Receptor Important for Alzheimer's Disease and Depression
November 7, 2022
Marvel Biosciences Successfully Completes Engineering Run of Its Lead Asset Targeting Alzheimer's Further Advancing Towards FDA Phase I Human Trials
November 1, 2022
Marvel Biosciences Advances Closer to Human Trials After the Successful Completion of a Second Maximum Tolerated Dose Study, a Critical Milestone Towards FDA Clinical Studies
October 25, 2022
Marvel Biosciences Successfully Completes Maximum Tolerated Dose Study, a Critical Milestone Towards FDA Clinical Studies
October 17, 2022
Marvel Biosciences Highlights Recent Research on the Serotonin Theory of Depression
October 4, 2022
Marvel Biosciences Highlights Recent Research on Link Between NASH and Alzheimer's Disease
August 31, 2022
Marvel Biosciences Closes Second Tranche of Private Placement
August 9, 2022
Marvel Announces Identification of a Novel Formulation of Its MB-204 Asset
July 21, 2022
Marvel Biosciences Closes First Tranche of Private Placement
July 18, 2022
Marvel Biosciences Announces Non-Brokered Private Placement
June 21, 2022
Marvel Biosciences Initiates Formulation Development with Catalent
April 6, 2022
Marvel Biosciences Announces Second Quarter 2022 Financial Results
March 30, 2022
Marvel Biosciences Announces Proxy Tabulation and Shareholder Meeting Results
February 16, 2022
Marvel Biosciences Provides Corporate Update as it Enters a Significant Value Creating Phase
February 8, 2022
Marvel Biosciences Corp. Announces Change of Chief Financial Officer
February 1, 2022
Marvel Biosciences Completes Manufacturing Engineering Run of Lead Asset MB-204
December 16, 2021
Marvel Biosciences Achieves CGMP Milestone and Begins IND-Enabling Pre-Clinical Toxicology Testing of Lead Compound
December 8, 2021
Keynotes, Educational Panels and 70 Companies to Present at the SNN Network Canada Virtual Event on December 7-9, 2021
December 6, 2021
Marvel Biosciences to Present at the SNN Network Canada Virtual Event on Wednesday, December 8, 2021
December 3, 2021
Marvel Biosciences to Host Investor Webinar
November 29, 2021
Marvel Biosciences Lead Asset MB-204 Show 47% Reduction in Liver Fibrosis and Active Indications in Multiple Pre-Clinical Models of Nash
November 23, 2021
Marvel Biosciences Appoints Scientific Advisory Board
November 9, 2021
Marvel Biosciences Announces New Program to Develop Novel Orally Dosed Non-Hallucinogenic Neuroplastic Promoting Compounds
October 27, 2021
Marvel Biosciences Provides Updates on the Status of Its MB-204 Manufacturing Efforts and Sets Out Future Milestones
October 15, 2021
Marvel Biosciences Corp. to Present at the 22nd International Conference on Alzheimer's Drug Discovery
September 17, 2021
Marvel Biosciences Corp. Updates Market on Its Lead Caffeine Inspired Asset MB-204 for Neurological Diseases
August 5, 2021
Marvel Biosciences Corp. Retains Virtus Advisory Group to Provide Corporate Communications Services
August 3, 2021
Marvel Biosciences Corp. to Commence cGMP Manufacturing of Its Lead Asset MB-204
July 21, 2021
IIROC Trading Resumption - MRVL
July 9, 2021
Alphanco Venture Corp. Changes Name to Marvel Biosciences Corp. and Completes Acquisition of Marvel Biotechnology Inc.
July 8, 2021
IIROC Trading Halt - AVC.P
October 28, 2020
IIROC Trading Resumption - AVC.P
March 1, 2019